Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes October 13, 2026 4:30 PM EDT
Company Participants
Greg Mann – Senior Vice President of Investor Relations & Corporate Affairs
Troy Wilson – Chairman, CEO & President
Francis Burrows – Chief Scientific Officer
Robert Spencer
Conference Call Participants
Nabeel Nissar – Jefferies LLC, Research Division
Priyanka Grover – JPMorgan Chase & Co, Research Division
Li Wang Watsek – Cantor Fitzgerald & Co., Research Division
Jason Zemansky – BofA Securities, Research Division
Peter Green – LifeSci Capital, LLC, Research Division
Philip Nadeau – TD Cowen, Research Division
Reni Benjamin – Citizens JMP Securities, LLC, Research Division
Daniel Brims – Lake Street Capital Markets, LLC, Research Division
Presentation
Operator
Good day, everyone. My name is Ryan, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology and Caspian Therapeutics Investors Call. [Operator Instructions]
At this time, I’d like to turn the call over to Greg Mann, Senior Vice President, Investor Relations and Corporate Affairs.
Greg Mann
Senior Vice President of Investor Relations & Corporate Affairs
Good afternoon, and welcome to the Kura Oncology and Caspian Therapeutics Investor Call on KO-7246 in diabetes. We remind you that today’s discussion will include forward-looking statements based on current expectations. Such statements represent management’s judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from expected response. Please refer to Kura’s filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company.
I’ll now turn the call over to Dr. Troy Wilson, President and Chief Executive Officer of Kura Oncology and Executive Chairman of Caspian Therapeutics. Troy, please go ahead.
Troy Wilson
Chairman, CEO & President
